Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
You may also be interested in...
Transformation Into Viatris Not Seen As The Solution Mylan Needs
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
Biocon And Mylan's Fulphila And Insulin Plans On Track
Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.